Analysts are slightly more optimistic about Veracyte's losses per share, but expect its revenue growth to slow down substantially compared to its historical 29% growth rate. The wider industry is expected to outpace Veracyte.
The absence of any insider transactions in the past three months doesn't reveal much. Low insider ownership and previous insider selling at Veracyte sparks less enthusiasm. Investors should be aware of potential risks associated with the company.
Gainers: •$テラバンス・バイオファーマ(TBPH.US)$+15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln) •$Amryt Pharma(AMYT.US)$+11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome) •$グリーンブリック・パートナーズ(GRBK.US)$+7.3% (to join S&P SmallCap 600) •$TransGlobe Energy(TGA.US)$+6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
搞经济 抄底 加仓 :
I though I got the dip , till news out that ARK came on board. I know this is not the end.. Average Down^together 还以为抄底了 知道木头也买了。。那一瞬间我知道那不是低点了。。。哇c
$ヴェラサイト(VCYT.US)$ Veracyte announced that it has begun rolling out its long-awaited nasal swab test for lung cancer at a limited number of clinical sites, as the company continues to accumulate data to support its future full commercial rollout. The company also published recent findings showing that the Percepta Genomic test can more accurately group patients based on their risk of developing tumors and suspicious lung nodules.
ヴェラサイトに関するコメント
コラムToday's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Select biotech/pharma names showing strength following ESMO:
$クロビス・オンコロジー(CLVS.US)$ +11.3%, $カーディフ・オンコロジー(CRDF.US)$ +9%, $イマティクス(IMTX.US)$ +8.3%, $IDEAYAバイオサイエンシズ(IDYA.US)$ +8%, $ライラ・セラピューティクス(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $エッジワイズ・セラピューティクス(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $デシフィラ・ファーマシューティカルズ(DCPH.US)$ +3.2%, $ヴェラサイト(VCYT.US)$ +2.6%, $スプリングワークス・セラピューティクス(SWTX.US)$ +2.3%,...
コラムToday's pre-market stock movers: TSLA, JPM, NVAX, CAG and more
• $テラバンス・バイオファーマ(TBPH.US)$ +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
• $Amryt Pharma(AMYT.US)$ +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
• $グリーンブリック・パートナーズ(GRBK.US)$ +7.3% (to join S&P SmallCap 600)
• $TransGlobe Energy(TGA.US)$ +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
コラムToday's pre-market stock movers: SE, AMD, WMT, JD and more
• $マイクロヴァスト・ホールディングス(MVST.US)$ +14.6% (In reaction to earnings)
• $シー(SE.US)$ +11.3% (Q1 adjusted loss expands, revenue jumps)
• $JD.COM(京東商城)(JD.US)$ +9.1% (beating top-line and bottom-line estimates for its latest quarter)
• $コインベース(COIN.US)$ +6.3% (announces it is "slowing hiring so we can reprioritize our hiring needs against our highest-priority business goals")
• $ヘリオゲン(HLGN.US)$ +5%(to restate Full Year 2021 Financials)
• $テイクツー・インタラクティブ・ソフトウエア(TTWO.US)$ +4.9% (de...
コラムToday's pre-market stock movers: TSLA, TWTR, AFRM, DWAC and more
• $アファーム・ホールディングス(AFRM.US)$ +36.4% (also announces multi-year extension of exclusive partnership with SHOP in the US)
• $ロビンフッド・マーケッツ(HOOD.US)$ +22.9% (Emergent Fidelity discloses 7.6% stake; Sam Bankman-Fried CEO of crypto exchange FTX is majority holder in fund)
• $エンデバー・グループ・ホールディングス(EDR.US)$ +20% (in reaction to earnings)
• $コインベース(COIN.US)$ +13% (in sympathy with HOOD news)
• $ダイナバクス・テクノロジーズ(DVAX.US)$ +11.5% (to join ...
ARK's buys and sells (Dec.16)
ARK's buys
$ロビンフッド・マーケッツ(HOOD.US)$$NUホールディングス(NU.US)$$ヴェラサイト(VCYT.US)$$パーソナリス(PSNL.US)$$ページャーデューティー(PD.US)$$クアンタム・シイ(QSI.US)$
ARK's sells
$アイオバンス・バイオセラピューティクス(IOVA.US)$$ライブパーソン(LPSN.US)$$スリーディー・システムズ(DDD.US)$
Veracyte announced that it has begun rolling out its long-awaited nasal swab test for lung cancer at a limited number of clinical sites, as the company continues to accumulate data to support its future full commercial rollout.
The company also published recent findings showing that the Percepta Genomic test can more accurately group patients based on their risk of developing tumors and suspicious lung nodules.
まだコメントはありません